Hemovent GmbH is a German startup that was founded in 2013. This innovative company is dedicated to Rethinking heart-lung support, with a specific focus on the essential requirements of patients and their treating physicians in critical situations where extracorporeal support is necessary. Their innovations and solutions are aimed at redefining the field of Extracorporeal Life Support (ECLS and ECMO) with full attention, strict focus, and easy access. Hemovent GmbH operates in the Biotechnology and Healthcare industries, reflecting its commitment to addressing crucial medical needs. Hemovent GmbH secured a significant $5.20M Series B investment on 14th February 2019, demonstrating strong support and confidence from investors. Although the specific investors are not disclosed, this substantial investment indicates a strong belief in the company's vision and potential. This recent investment contributes to the company's growth and development, potentially enabling them to further advance their innovative solutions and make a meaningful impact in the medical field.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $5.20M | - | 14 Feb 2019 | |
| Series A | €2.00M | 4 |
|
25 Jul 2017 |
| Series A | $6.00M | 6 |
|
10 Feb 2016 |
No recent news or press coverage available for Hemovent GmbH.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
